Reliable Monitoring of Antiviral Therapy of Hepatitis C Infections

Hepatitis C (HCV) infection is the most common cause of liver cell carcinoma and liver transplants in Europe

Analytik Jena
Sep 17, 2017

Jena, Germany, September 14, 2017 – Hepatitis C (HCV) infection is the most common cause of liver cell carcinoma and liver transplants in Europe, which are possible late-stage effects of a chronic infection, alongside cirrhosis of the liver. An antiviral therapy to eliminate the hepatitis C virus allows a treatment and curing of the infection. The standardized approach for monitoring the effectiveness of the therapy involves the repeated quantitative measurement of the patient’s HCV RNA levels. This requires the use of a highly sensitive HCV RNA assay.

The CE-IVD certified workflow from Analytik Jena, including the INSTANT Virus RNA/DNA Kit for nucleic acid purification in combination with the RoboGene® HCV RNA Quantification Kit 3.0 for nucleic acid detection on the Real-Time PCR Cycler qTOWER³ offers a reliable solution. With a detection limit 17 IU/ml the RoboGene® HCV RNA Quantification Kit 3.0 allows a highly sensitive quantitative analysis of HCV RNA...

More information about requirements and solutions for a reliable monitoring of the therapeutic effectiveness of HCV treatment and the recovery process on https://www.analytik-jena.de/en/clinical.html.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?